Pharmaceutical

BeiGene to acquire DualityBio’s ADC therapy for solid tumours

BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.

Jul 11, 2023 - 20:00
BeiGene to acquire DualityBio’s ADC therapy for solid tumours
BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.
Read the original article

Tags:

Previous Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

Next Article

Elsie and GSK link to accelerate oligonucleotide discovery platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

STAT+: Federal judge rules against AstraZeneca in lawsu...

Mar 2, 2024

Selinexor by Karyopharm Therapeutics for Wilms’ Tumor (...

Oct 27, 2023

FDA approves Syndax’s Revuforj to treat leukaemia

FDA approves Syndax’s Revuforj to treat leukaemia

Nov 19, 2024